The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 7, 2010, Pages 884-893

  Wong, B S ^a   Rao, A S ^a   Camilleri, M ^a   Manabe, N ^a   McKinzie, S ^a   Busciglio, I ^a   Burton, D D ^a   Ryks, M ^a   Zinsmeister, A R ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; CODEINE;

ADULT; ARTICLE; BLOATING; CANCER FATIGUE; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FECES COMPOSITION; FEMALE; FLATULENCE; FOOD INTAKE; GASTROINTESTINAL TRANSIT; HUMAN; HUMAN EXPERIMENT; INJECTION SITE BURNING; INTESTINE FUNCTION; INTESTINE MOTILITY; MALE; MUSCULOSKELETAL PAIN; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STOMACH EMPTYING; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; CODEINE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, OPIOID, MU; YOUNG ADULT;

EID: 77956408794     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04422.x     Document Type: Article

References (31)

1. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 2007 41 : 984 993.
2. McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev (Online) 2008 2 : CD006332.
3. Moss J, Rosow CE. Development of peripheral opioid antagonists' new insights into opioid effects. Mayo Clin Proc 2008 83 : 1116 1130.
4. Sternini C, Spann M, Anton B, et al. Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci U S A 1996 93 : 9241 9246.
5. De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004 16 : 383 394.
6. Gonenne J, Camilleri M, Ferber I, et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005 3 : 784 791.
7. Hawkes ND, Richardson C, Evans BK, Rhodes J, Lewis SJ, Thomas GA. Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine. Aliment Pharmacol Ther 2001 15 : 625 630.
8. Talley NJ, Phillips SF, Wiltgen CM, Zinsmeister AR, Melton LJ III. Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc 1990 65 : 1456 1479.
9. Manabe N, Cremonini F, Camilleri M, Sandborn WJ, Burton DD. Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Aliment Pharmacol Ther 2009 30 : 930 936.
10. Codeine. DRUGDEX® System. Greenwood Village, CO : Thomson Reuters (Healthcare), Inc., n.d. Available at: http://www.thomsonhc.com. Accessed July 9, 2010.
11. Deiteren A, Camilleri M, Bharucha AE, et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil 2010 22 : 415 423, e95.
12. Camilleri M. Scintigraphic biomarkers for colonic dysmotility. Clin Pharmacol Ther 2010 87 : 748 753.
13. Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med 1997 38 : 1807 1810.
14. Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002 16 : 1781 1790.
15. Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985 24 : 181 191.
16. Russell J, Bass P, Goldberg LI, Schuster CR, Merz H. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 1982 78 : 255 261.
17. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Eng J Med 2008 358 : 2332 2343.
18. Yuan CS, Foss JF. Oral methylnaltrexone for opioid-induced constipation. JAMA 2000 284 : 1383 1384.
19. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000 283 : 367 372.
20. Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, Moss J. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain 1999 83 : 631 635.
21. Earnshaw SR, Klok RM, Iyer S, McDade C. Review article: methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness - a cost-effectiveness analysis. Aliment Pharmacol Ther 2010 31 : 911 921.
22. Yuan CS, Doshan H, Charney MR, et al. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 2005 45 : 538 546.
23. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Eng J Med 2003 349 : 1943 1953.
24. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008 137 : 428 440.
25. Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment-randomized clinical trial. J Pain 2005 6 : 184 192.
26. Taguchi A, Sharma N, Saleem RM, et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Eng J Med 2001 345 : 935 940.
27. Turnberg LA. Antisecretory activity of opiates in vitro and in vivo in man. Scand J Gastroenterol Suppl 1983 84 : 79 83.
28. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004 16 (Suppl. 2 17 28.
29. Woo M, O'Connor M, Yuan CS, Moss J. Reversal of opioid-induced gastric dysfunction in a critically ill burn patient after methylnaltrexone. Anesth Analg 2008 107 : 1965 1967.
30. Yuan CS, Foss JF, O'Connor M, et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther 2000 67 : 398 404.
31. Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss J. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 1997 61 : 467 475.